Regulatory press release

Indical Bioscience, part of the Vimian group, acquires Salmonella and antimicrobial resistance diagnostics company

Indical Bioscience, the operating company within Vimian’s Diagnostics segment, has signed an agreement to acquire Check-Points. Check-Points is a Dutch molecular diagnostics company specialising in Salmonella typing for the food and veterinary market as well as antimicrobial resistance detection for human applications.

Check-Points is a Dutch R&D focused company that produces tests for two principal markets – food safety and human antimicrobial resistance. The main component of the business is related to “Check and Trace”, a unique product based on a microarray platform to accurately identify over 300 serotypes of Salmonella. The company, founded in 2002 with annual revenues of approximately EUR 2.3 million, also produces a number of DNA-based tests for the molecular detection of antimicrobial resistance in hospital acquired infections in humans.

Through the Salmonella test, the company principally serves producers and labs within the poultry industry as well as food safety labs. The human assays principally target in-hospital laboratories.

“The acquisition of Check-Points bolsters our poultry portfolio and direct-to-producer offering but also represents a first step for Indical into food safety and antimicrobial resistance segments. Check-Points has developed strong momentum in its core products and has an exciting R&D pipeline, with highly relevant development expertise that can support new projects within Indical itself. We look forward to working with the Check-Points management team to take advantage of all these opportunities”, says Stefano Santarelli, CEO of Indical Bioscience.

“Joining forces with Indical will allow us to extend the worldwide footprint of our unique, innovative products. We are excited about this wonderful opportunity for our company”, says Pieter Vos, CEO of Check-Points.

The acquisition will have a marginal impact on Vimian Group AB's earnings per share in the current financial year.

About Indical Bioscience
Indical Bioscience, the operating company within Vimian’s Diagnostics segment, is a global leader in the development of complete solutions for molecular and immunological veterinary testing to identify, prevent, monitor, and eradicate animal diseases. The offering is suited to both the livestock and companion animal health markets. The products and workflows for veterinary diagnostics and pathogen research are trusted by lab technicians, vets, and organizations worldwide, including government agencies, laboratories, research institutes, farmers, and producers.

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 400 people and have a combined annual turnover of approximately EUR 140 million. For more information, please visit: www.vimian.com.